Raymond James Financial
ABUS icon

Raymond James Financial’s Arbutus Biopharma ABUS Stock Holding History

Raymond James Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-191,355
Closed -$861K – 5398
2026
Q1 		$861K Buy
191,355
+131,170
+218% +$574K ﹤0.01% 3968
2025
Q4 		$289K Buy
+60,185
New +$271K ﹤0.01% 4599
2025
Q3 		– Sell
-8,504
Closed -$26.3K – 4965
2025
Q2 		$26.3K Sell
8,504
-2,000
-19% -$6.64K ﹤0.01% 5475
2025
Q1 		$36.7K Hold
10,504
– – ﹤0.01% 4665
2024
Q4 		$34.3K Buy
+10,504
New +$38.6K ﹤0.01% 4660

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial's ABUS Position: Q2 2026 in Review

Raymond James Financial sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 191,355 shares — an estimated $861K sold.

Raymond James Financial first reported a position in ABUS in Q4 2024 and held it in 5 quarters. The position peaked at $861K in Q1 2026. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Raymond James Financial reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 191,355 Arbutus Biopharma shares in Q2 2026, an estimated $861K.
  • Raymond James Financial first reported a position in Arbutus Biopharma in Q4 2024 and held it in 5 quarters.
  • Raymond James Financial's Arbutus Biopharma position peaked at $861K in Q1 2026.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.